CTRI/2021/07/034751尚未招募1 期
Phase 1/2 study of the efficacy 3 mg Peg GCSF in adjuvant and/or neoadjuvant dose dense breast cancer treatment protocols.
Abhishek Pathak0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Newly diagnosed female patients with invasive ductal carcinoma breast requiring neoadjuvant or adjuvant dd-AC/EC protocol.
排除标准
- •1.Previous exposure to chemotherapy or radiotherapy.
- •2.Patients suffering from other causes of myelosuppression (aplastic anemia, drug related, viral infection)
- •3.HbsAg or anti HCV positive patients.
- •4.Uncontrolled diabetes mellitus, HbA1C > 7.5 g%
- •5.History of severe Covid in last 06 months
研究者
相似试验
进行中（未招募）
不适用
A single arm phase 2 study on the efficacy of Pegfilgrastim (Neulasta) after DCEP chemotherapy: a feasibility study in multiple myeloma patients eligible for autologous transplant. - NDMedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myelomamultiple myelomaEUCTR2008-000103-29-ITOSPEDALE POLICLINICO S. MATTEO
招募中
2 期
A Phase2 study of the safety and efficacy of pegfilgrastism for the prevention of febrile neutropenia in patients receiving TPF therapy for squamous cell carcinoma of the head and neck.JPRN-jRCTs031220695Saito Yuki18
已完成
不适用
G-CSF in treatment of premature neonates with neutropenia and clinical sepsisneonatal sepsis.Other infectious diseasesIRCT201303252639N11Deputy for research of Shahid Sadoughi University of Medical Sciences , Yazd, Iran .40
进行中（未招募）
3 期
Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After ChemotherapyNeutropenia, Chemotherapy-Induced FebrileBreast Neoplasm FemaleNCT06711523Kexing Biopharm Co., Ltd.250
Unknown
2 期
Saftey and Efficacy of Pegfilgrastim in Preventing Chrmotherapy-induced NeutropeniaNeutropeniaNCT01918241Hangzhou Jiuyuan Gene Engineering Co. Ltd.,200